1 Reason to Buy Eli Lilly Hand Over Fist Before the New Year

Core Insights - Eli Lilly's stock has surpassed $1,000, driven by strong demand in the weight loss drug market, particularly for its products Mounjaro and Zepbound [1][4] - The company has seen over 100% stock growth in the past three years, with expectations for continued growth in both the short and long term [2] - A potential new growth driver is the weight loss pill orforglipron, which may significantly boost revenue starting in 2026 [5][9] Company Performance - Mounjaro and Zepbound are dual GIP/GLP-1 receptor agonists that have contributed to a revenue increase of over 50% in the third quarter [3][4] - Eli Lilly's current market capitalization is approximately $989 billion, with a gross margin of 83.03% and a dividend yield of 0.57% [7] Product Development - Orforglipron is positioned to be the world's first oral GLP-1 receptor agonist without dietary restrictions, potentially expanding the addressable market for Eli Lilly [8] - The company is investing billions in manufacturing capacity in Puerto Rico and Europe to support the production of orforglipron and other oral medications [7]